Expleo Solutions Inkomsten in het verleden
Verleden criteriumcontroles 2/6
Expleo Solutions has been growing earnings at an average annual rate of 25.8%, while the IT industry saw earnings growing at 20.4% annually. Revenues have been growing at an average rate of 31.9% per year. Expleo Solutions's return on equity is 15.4%, and it has net margins of 9.5%.
Belangrijke informatie
25.8%
Groei van de winst
16.1%
Groei van de winst per aandeel
| IT Groei van de industrie | 24.3% |
| Inkomstengroei | 31.9% |
| Rendement op eigen vermogen | 15.4% |
| Nettomarge | 9.5% |
| Volgende winstupdate | 14 Nov 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Expleo Solutions Limited's (NSE:EXPLEOSOL) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 24
When Should You Buy Expleo Solutions Limited (NSE:EXPLEOSOL)?
Jun 21Investors Could Be Concerned With Expleo Solutions' (NSE:EXPLEOSOL) Returns On Capital
Mar 15The Returns On Capital At Expleo Solutions (NSE:EXPLEOSOL) Don't Inspire Confidence
Sep 15Increases to Expleo Solutions Limited's (NSE:EXPLEOSOL) CEO Compensation Might Cool off for now
Aug 19Calculating The Fair Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)
Jul 14Many Would Be Envious Of Expleo Solutions' (NSE:EXPLEOSOL) Excellent Returns On Capital
May 05A Look At The Fair Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)
Mar 15Expleo Solutions Limited's (NSE:EXPLEOSOL) Stock Been Rising: Are Strong Financials Guiding The Market?
Feb 15
Expleo Solutions (NSE:EXPLEOSOL) Knows How to Allocate Capital
Jan 24Introducing Expleo Solutions (NSE:EXPLEOSOL), A Stock That Climbed 76% In The Last Year
Jan 04A Look At The Intrinsic Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)
Dec 14Is There More To The Story Than Expleo Solutions's (NSE:EXPLEOSOL) Earnings Growth?
Nov 26Opbrengsten en kosten
Hoe Expleo Solutions geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
| Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
|---|---|---|---|---|
| 30 Jun 24 | 9,919 | 942 | 0 | 0 |
| 31 Mar 24 | 9,649 | 904 | 23 | 0 |
| 31 Dec 23 | 9,405 | 1,038 | 16 | 0 |
| 30 Sep 23 | 9,305 | 1,251 | 16 | 0 |
| 30 Jun 23 | 9,152 | 1,311 | 16 | 0 |
| 31 Mar 23 | 9,033 | 1,339 | 16 | 0 |
| 31 Dec 22 | 5,072 | 823 | 6 | 0 |
| 30 Sep 22 | 4,779 | 648 | 6 | 0 |
| 30 Jun 22 | 4,439 | 583 | 6 | 0 |
| 31 Mar 22 | 7,425 | 677 | 9 | 0 |
| 31 Dec 21 | 3,703 | 463 | 4 | 0 |
| 30 Sep 21 | 3,366 | 475 | 4 | 0 |
| 30 Jun 21 | 3,131 | 490 | 4 | 0 |
| 31 Mar 21 | 3,009 | 504 | 4 | 0 |
| 31 Dec 20 | 2,971 | 534 | 4 | 0 |
| 30 Sep 20 | 2,931 | 512 | 4 | 0 |
| 30 Jun 20 | 2,852 | 475 | 4 | 0 |
| 31 Mar 20 | 2,702 | 399 | 4 | 0 |
| 31 Dec 19 | 2,627 | 353 | 28 | 0 |
| 30 Sep 19 | 2,614 | 298 | 28 | 0 |
| 30 Jun 19 | 2,741 | 345 | 28 | 0 |
| 31 Mar 19 | 2,865 | 362 | 28 | 0 |
| 31 Dec 18 | 2,973 | 372 | 27 | 0 |
| 30 Sep 18 | 2,949 | 377 | 27 | 0 |
| 30 Jun 18 | 2,898 | 313 | 27 | 0 |
| 31 Mar 18 | 2,764 | 320 | 27 | 0 |
| 31 Dec 17 | 2,583 | 256 | 573 | 0 |
| 30 Sep 17 | 2,488 | 243 | 573 | 0 |
| 30 Jun 17 | 2,475 | 230 | 573 | 0 |
| 31 Mar 17 | 2,599 | 238 | 29 | 0 |
| 31 Dec 16 | 2,747 | 293 | 402 | 0 |
| 30 Sep 16 | 2,809 | 329 | 402 | 0 |
| 30 Jun 16 | 2,790 | 372 | 402 | 0 |
| 31 Mar 16 | 2,642 | 369 | 402 | 0 |
| 31 Dec 15 | 2,445 | 279 | 290 | 0 |
| 30 Sep 15 | 2,312 | 271 | 290 | 0 |
| 30 Jun 15 | 2,212 | 240 | 290 | 0 |
| 31 Mar 15 | 2,142 | 216 | 391 | 0 |
| 31 Dec 14 | 2,116 | 222 | 301 | 0 |
| 30 Sep 14 | 2,087 | 226 | 301 | 0 |
| 30 Jun 14 | 2,027 | 261 | 301 | 0 |
| 31 Mar 14 | 1,944 | 300 | 301 | 0 |
| 31 Dec 13 | 1,819 | 300 | 305 | 0 |
Kwaliteitswinsten: EXPLEOSOL has high quality earnings.
Groeiende winstmarge: EXPLEOSOL's current net profit margins (9.5%) are lower than last year (14.3%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: EXPLEOSOL's earnings have grown significantly by 25.8% per year over the past 5 years.
Versnelling van de groei: EXPLEOSOL's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: EXPLEOSOL had negative earnings growth (-28.2%) over the past year, making it difficult to compare to the IT industry average (12.9%).
Rendement op eigen vermogen
Hoge ROE: EXPLEOSOL's Return on Equity (15.4%) is considered low.